Claudine Isaacs

Jan 14, 2025 | cancernetwork.com | Virginia Kaklamani |Claudine Isaacs |Elizabeth Diaz |Terri Harrington

January 14, 2025By Panelists discuss ongoing clinical trials and how the treatment landscape for HR positive (HR+)/ HER2 negative (HER2-) breast cancer is evolving with novel targeted therapies and combination strategies, with Dr Isaacs highlighting the most exciting aspects of these trials and their potential impact on the future of precision medicine in this patient population.

Jan 7, 2025 | cancernetwork.com | Virginia Kaklamani |Claudine Isaacs |Elizabeth Diaz |Terri Harrington

January 7, 2025By Panelists discuss how the evolving treatment landscape, particularly with the introduction of new agents, has influenced Ms. Diaz's approach to patient education, highlighting strategies for staying informed and proactive, as well as ensuring effective coordination of care across multidisciplinary teams to optimize patient outcomes.

Jan 7, 2025 | cancernetwork.com | Virginia Kaklamani |Claudine Isaacs |Elizabeth Diaz |Terri Harrington

January 7, 2025 By Panelists discuss strategies for patient education and monitoring hyperglycemia with PI3K inhibitors, including pre-treatment screening, baseline assessments, early recognition of adverse events, and supportive care measures such as dietary modifications, with Ms. Harrington sharing practical approaches and helpful resources; Dr Isaacs comments on potential differences in adverse event management, particularly hyperglycemia, between inavolisib, capivasertib, and alpelisib,...

Dec 17, 2024 | cancernetwork.com | Virginia Kaklamani |Claudine Isaacs |Elizabeth Diaz |Terri Harrington

2 Commerce Drive Cranbury, NJ 08512

Sep 29, 2024 | nature.com | CHRISTOPHER GALLAGHER |Claudine Isaacs

AbstractUnderrepresented populations’ participation in clinical trials remains limited, and the potential impact of genomic variants on drug metabolism remains elusive. This study aimed to assess the pharmacokinetics (PK) and pharmacogenomics (PGx) of ribociclib in self-identified Black women with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2) advanced breast cancer.